Clinical trials: Histological Type of Neoplasm
Refractory Multiple Myeloma
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma
- Trial name
- NCT00912899
- Testing
- Noscapine HCl
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cougar Biotechnology, Inc.
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter
Named Patient Program for Mitomycin for Pyelocalyceal Solution
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named…
- Conditions
- Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
- Trial name
- NCT05494411
- Testing
- Mitomycin for pyelocalyceal solution
- Sponsor
- UroGen Pharma Ltd.
Multiple Myeloma
PRospective Multiple Myeloma Impact Study
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
- Trial name
- PROMMIS (NCT02911571)
- Testing
- MMprofiler SKY92 gene signature
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- SkylineDx
Multiple Myeloma
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is an open-label, multicenter, Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple…
- Trial name
- EVOLVE (NCT03430011)
- Testing
- JCARH125, JCARH125 + anakinra
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Carcinoma, Adenocarcinoma
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
- Conditions
- Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma
- Trial name
- NCT00719264
- Testing
- RAD001(everolimus), interferon alfa-2a, bevacizumab
- Where
- 109 sites in United States, Belgium and 19 more
- Volunteers
- 365 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally…
- Trial name
- SAFFRON (NCT05261399)
- Testing
- Savolitinib, Osimertinib, Pemetrexed
- Where
- 214 sites in United States, Argentina and 25 more
- Volunteers
- 341 people
- Sponsor
- AstraZeneca
Recurrent Gliomas
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
This study will evaluate the safety and effectiveness of Enzastaurin, an experimental drug that may prevent the growth of tumor vessels, in combination with Carboplatin, for patients who have a glioma, a type of brain tumor.
- Trial name
- NCT01445119
- Testing
- Enzastaurin (LY317615), Carboplatin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Eli Lilly and Company
Head and Neck Squamous Cell Carcinoma
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Phase II Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic Head and Neck cancer previously pre-treated with a platinum therapy.The primary endpoint was…
- Trial name
- NCT01852292
- Testing
- Buparlisib, Paclitaxel
- Where
- 58 sites in United States, Australia and 16 more
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Non-Small Cell Lung Cancer
131-I-TM-601 Study in Adults With Solid Tumors
This study is designed to evaluate the ability of intravenously (IV)administered 131-I-labeled TM-601 (chlorotoxin) to provide tumor-specific localization(via radiographic imaging) in patients with recurrent or refractory primary…
- Conditions
- Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer
- Trial name
- NCT00379132
- Testing
- 131-I-TM-601 (chlorotoxin)
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- TransMolecular
Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer)
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer
- Trial name
- NEUTROFLOW (NCT07246759)
- Testing
- Blood sample collection
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- OncoHost Ltd.
Lymphoma
Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00041379
- Testing
- beta alethine
- Where
- United States
- Sponsor
- LifeTime Pharmaceuticals
Hepatocellular Carcinoma
Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma
The primary objective of this study is to answer the question "Is it possible to inject the COMBIG-DC vaccine in a hepatic tumor without getting unacceptable side effects"?
- Trial name
- NCT01974661
- Testing
- COMBIG-DC (ilixadencel)
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Mendus
Multiple Myeloma
Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Objective of this study is to characterize the steady-state pharmacokinetics (PK) of thalidomide when given orally as monotherapy to subjects with multiple myeloma.
- Trial name
- NCT01937442
- Testing
- Thalidomide Celgene™
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Celgene
Glioblastoma Multiforme
TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
The study is a prospective, single arm open label study, designed to test the to evaluate the tolerability and safety outcome of newly diagnosed GBM patients treated with NovoTTF-200A concomitant to Radiotherapy/Temozolomide…
- Trial name
- NCT03780569
- Testing
- NovoTTF-200A, Radiotherapy, Temozolomide
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- NovoCure Ltd.
Breast Cancer, Lung Cancer
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- TRT-001 (NCT02960594)
- Testing
- INO-1400, INO-9012, INO-1401
- Where
- 6 sites in United States
- Volunteers
- 93 people
- Sponsor
- Inovio Pharmaceuticals
Melanoma
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with ipilimumab; and then to evaluate the anti-tumor response to BMS-908662 when administered in combination with ipilimumab.
- Trial name
- NCT01245556
- Testing
- BMS-908662, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Yervoy Pregnancy Surveillance Study
The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age
- Trial name
- NCT02854488
- Testing
- Yervoy
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia
Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)
This Phase I study is designed to assess the safety, tolerability, pharmacokinetics and anti-tumor effect of increasing doses of study drug SKI-G-801 in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are…
- Trial name
- NCT03564288
- Testing
- SKI-G-801
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Oscotec Inc.
Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
This is a Phase 1 multi-center study to evaluate the clinical safety and immune response of ID-LV305 when injected intradermally in patients with advanced cancer.
- Conditions
- Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed, Sarcoma - Enrollment Completed
- Trial name
- NCT02122861
- Testing
- ID-LV305
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Leiomyoma, Uterine Fibroids
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
The primary objective of this study is to test the hypothesis that a minimum 75% volume radiofrequency ablation of fibroids associated with menorrhagia results in reduction of menstrual bleeding.
- Conditions
- Leiomyoma, Uterine Fibroids, Menorrhagia
- Trial name
- FAST (NCT00768742)
- Testing
- VizAblate Intrauterine Ultrasound-Guided RF Ablation
- Where
- 3 sites in Canada
- Sponsor
- Gynesonics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.